Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly versus every-3-week cisplatin during chemoradiation for head and neck epithelial carcinoma
IRCT20180223038829N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of cisplatin in head and neck cancer (HNC) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Leukocyte change, Neutrophil change and 5 more. Started Mar 2016; status: completed.
02
Drugs
cisplatin
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on IRCT20180223038829N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180223038829N1.